BioVectra Inc.

17 articles about BioVectra Inc.

• BIOVECTRA Signs Service Agreement With Acuitas Therapeutics for Unique Lipid Nanoparticle (LNP) Delivery System Used in Manufacturing mRNA-Based Therapies

  10/5/2023

  BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service agreement under which BIOVECTRA will accept, on a non-exclusive basis, Acuitas’ best-in-class LNP technology platform for manufacturing mRNA-based therapeutics.

• BIOVECTRA mRNA Vaccine and Bio-Manufacturing Facility Announced

  11/18/2021

  BIOVECTRA announced plans for the development of a state-of-the-art facility specializing in the production and manufacturing of mRNA vaccines and therapeutics – one of the first of its kind in Canada.

• BIOVECTRA Announces Appointment of Steven M. Klosk and Gordon C. Mccauley to Board

  10/21/2021

  BIOVECTRA , a leading Canadian biotech and pharmaceutical CDMO has appointed Gordon C. McCauley, President and CEO of adMare BioInnovations and Steven Klosk CEO (retired) Cambrex Corporation, to its board of directors.

• BIOVECTRA Inc. Looks Inward for New Brand: It’s All About Care

  6/2/2021

  BIOVECTRA Inc., a forward-thinking global contract development and manufacturing organization, launched a new logo and brand to align with the growing company’s full suite of expertise and core values.

• PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab

  3/11/2021

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, and BioVectra Inc., an innovative global contract development and manufacturing organization (CDMO), today announced a commercial scale supply agreement for the production of bentracimab,

• Mallinckrodt Completes Sale of BioVectra Inc. for up to $250 Million

  11/4/2019

  Milestone reinforces Company's ongoing strategic efforts to focus on branded, high-growth biopharmaceuticals by monetizing a non-core business

• H.I.G. Capital Completes Acquisition of BioVectra

  11/4/2019

  Founded in 1970, BioVectra’s core competencies include microbial fermentation, complex chemistry, high potency, and biologics.

• Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital for $250 Million

  9/10/2019

  Mallinckrodt plc announced it has entered into a definitive agreement to sell its wholly owned subsidiary BioVectra Inc.

• BioVectra Inc. Announces a $144.6 Million Expansion Project, Including a $37.5 Million Contribution Through the Government of Canada’s Strategic Innovation Fund

  3/12/2019

  Prime Minister Justin Trudeau visits BioVectra to announce Government of Canada investment in Atlantic Canadian CDMO and high-skilled jobs creation in the region

• BioVectra and Keryx Biopharma Enter Agreement for Ferric Citrate Production Expansion

  12/14/2017

  BioVectra today announced a long-term supply agreement with Keryx Biopharma to manufacture Ferric Citrate, the API in Auryxia tablets.

• BioVectra Inc. Named Agent of Reagent Proteins' Products

  6/25/2013

• Questcor Pharmaceuticals, Inc. (Headquarters) Announces Purchase of BioVectra Inc. for $50.7 Million Upfront

  1/3/2013

• BioVectra Inc. Confirms Partnership With Sandoz, Inc. to Market Docetaxel in the U.S.A.

  1/5/2010

• BioVectra Inc. Announces Oncolix Inc. Signs Manufacturing and Investment Agreement

  9/23/2009

• Therapure Biopharma Inc. Announces Collaboration with BioVectra Inc.

  11/4/2008

• Kane Biotech Inc. Retains BioVectra to Manufacture DispersinB(TM)

  3/4/2008

• Helix Biopharma Signs L-DOS47 Manufacturing Agreement With BioVectra DCL

  1/5/2007